Table 1 Baseline characteristics
Intervention (n = 17) | Usual care (n = 22) | P-value* | |
|---|---|---|---|
Mean age, years (Standard deviation) | 53.5 (12.5) | 44.7 (12.8) | 0.039 |
Gender | 1.000 | ||
Males (%) | 9 (52.9 %) | 12 (54.5 %) | |
Females (%) | 8 (47.1 %) | 10 (45.5 %) | |
Race | 0.634 | ||
White/Caucasian (%) | 12 (70.6 %) | 17(77.3 %) | |
Black/African Am. (%) | 2 (11.8 %) | 2 (9.1 %) | |
Othera | 1(5.9 %) | 1(4.5 %) | |
Not Reported (%) | 2 (11.8 %) | 2 (9.1 %) | |
Ethnicity | 1.000 | ||
Hispanic (%) | 0 | 1 (4.5 %) | |
Non-Hispanic (%) | 15 (88.2 %) | 17 (77.3 %) | |
Not Reported (%) | 2 (11.8 %) | 4 (18.2 %) | |
Colonization | |||
MSSA at baseline | 0 | 6 (27.3 %) | 0.063 |
MRSA at baseline | 2 (11.8 %) | 0 | 0.194 |
MSSA at discharge | 1 (7.1 %) | 4 (26.7 %) | 0.330 |
MRSA at discharge | 1 (6.7 %) | 0 | 1.000 |
Average cigarettes per day (SD) | 17.6 (9.0) | 16.5 (11.5) | 0.944 |
Infection history | |||
History of VRE (%) | 0 | 0 | - |
History of MRSA (%) | 0 | 1(4.5 %) | 1.000 |
History of C. difficile (%) | 0 | 0 | - |
Hosp history | |||
Hospitalized 3months. prior (%) | 2 (11.8 %) | 5 (22.7 %) | 0.438 |
Surgery 3months. prior (%) | 2 (11.8 %) | 3 (13.6 %) | 1.000 |
Immuno comp. status | |||
Active Cancer (%) | 5 (29.4 %) | 1 (4.5 %) | 0.068 |
Immunosuppressive Drugs 30 days prior (%) | 2 (11.8 %) | 2 (9.1 %) | 1.000 |
Diabetes (%) | 3 (17.6 %) | 6 (27.3 %) | 0.704 |
Comorbidities | |||
Liver disease (%) | 1 (5.9 %) | 4 (18.2 %) | 0.363 |
Cardiovascular disease (%) | 10 (58.9 %) | 10 (45.5 %) | 0.523 |
Respiratory disease (%) | 7 (41.2 %) | 10 (45.5 %) | 1.000 |
GI disease (%) | 6 (35.3 %) | 9 (40.9 %) | 0.753 |
Antibiotics | |||
Antibiotics within 30 days prior to admission (%) | 3 (17.6 %) | 6 (27.3 %) | 0.704 |
Other risk factors | |||
Open Wound (%) | 4 (23.5 %) | 7 (31.8 %) | 0.725 |
Alcohol Use (%) | 13 (76.5 %) | 13 (59.1 %) | 0.456 |
Drug Use (%) | 3 (17.6 %) | 4 (18.2 %) | 1.000 |
AVG. length of stay (SD)* | 5.2 (2.0) | 4.2 (2.8) | 0.227 |